Thomson PharmaSM - Integration enhances communication
Thomson Scientific, part of the Thomson Corporation, is a global leader in providing integrated information solutions to professionals working at all stages of the drug lifecycle. For decades, we have provided authoritative content to the Pharmaceutical and Biotechnology markets. With the launch of Thomson PharmaSM, which integrates this content into a customizable workflow solution, we are re-engineering the drug development process.
Current trends indicate that key departments and teams within organizations have overlapping data requirements, but need to process that data in a variety of different ways. This data is much easier to access and share if it's available through one integrated solution.
Thomson Pharma integrates the best of the drug, intellectual property, literature and news, company, target, chemistry, and sequencing content owned by Thomson in a single solution. It enables professionals working at all stages of the drug development pipeline, from clinical researchers and chemists to competitive intelligence and licensing and business development professionals, to annotate and share a common source of integrated information.
By combining powerful annotation and file sharing features with premium content, Thomson Pharma encourages collaboration, enhances communication, and expedites decision-making across departments and enhances an organization's ability to innovate, work faster and smarter, and attain outstanding research and business results.
Thomson Pharma
can help your organization to:
To find out more, visit: www.thomsonpharma.com
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
FDA Approves Stelara Biosimilar Selarsdi to Treat Psoriasis, Psoriatic Arthritis
April 17th 2024Alvotech’s and Teva's Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for patients aged 6 years and above with active psoriatic arthritis.